The pharmaceutical company forecasts business earnings per share growth at a low double-digit percentage and plans to launch ...

Head of Investor Relations Welcome to the Q4 and full year 2024 conference call for investors and analysts. As usual, you can find the slides on sanofi.com. Please turn to Slide 3. Here we have the ...

While Sanofi’s immunology megablockbuster Dupixent predictably dominated the company’s sales charts in 2024, a new golden ...

Sanofi has removed a clutch of programs from its clinical pipeline, scratching out entries for its late-phase BTK inhibitor and phase 1 prospects linked to the multibillion-dollar takeovers of Ablynx, ...

Sanofi SA (SNY) stock saw a decline, ending the day at $52.15 which represents a decrease of $-0.82 or -1.55% from the prior close of $52.97. The stock opened at $52.84 and touched a low of $52.14 ...

Deutsche Bank upgraded Sanofi (SNY) to Hold from Sell with a price target of EUR 100, up from EUR 85, following the company’s “solid” Q4 ...

Sanofi’s jump in earnings comes with an increased emphasis on R&D and vaccines, plus an eye cast toward M&A to shore up its pipeline.

Reports Business EPS of EUR 1.31, down 11.0% at CER and down 14.9% reported. Reports Q4 IRFS net sales EUR 10.56B, up 9.1% reported and up ...

Sanofi CFO François Roger signals increased M&A activity, eyes China for innovation, as company expects cash from Opella sale and plans €5B share buyback.

BUSINESS OPERATING PROFIT FORECAST: Business operating profit--one of the company's preferred metrics, which strips out exceptional items--is forecast at 2.08 billion euros, according to the Vara ...

Despite receiving a prior wrist slap from the FDA in the shape of a Form 483, Sanofi is still working to right the ship at a ...

Sanofi (SNY) on Thursday reported fourth-quarter earnings of $728.6 million. The company said it had net income of 29 cents per share. Earnings, adjusted for non-recurring costs and to account for ...